2.76
price up icon6.15%   0.16
after-market Dopo l'orario di chiusura: 2.76
loading
Precedente Chiudi:
$2.60
Aprire:
$2.58
Volume 24 ore:
1.24M
Relative Volume:
1.31
Capitalizzazione di mercato:
$473.67M
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-8.3636
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
+6.15%
1M Prestazione:
-2.47%
6M Prestazione:
-34.29%
1 anno Prestazione:
-43.56%
Intervallo 1D:
Value
$2.58
$2.92
Intervallo di 1 settimana:
Value
$2.425
$2.92
Portata 52W:
Value
$2.31
$5.34

Savara Inc Stock (SVRA) Company Profile

Name
Nome
Savara Inc
Name
Telefono
51285113796
Name
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Name
Dipendente
37
Name
Cinguettio
@SavaraPharma
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SVRA's Discussions on Twitter

Confronta SVRA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SVRA
Savara Inc
2.76 473.67M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Savara Inc Stock (SVRA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-20 Iniziato Wells Fargo Overweight
2024-11-13 Downgrade Evercore ISI Outperform → In-line
2024-02-15 Iniziato JMP Securities Mkt Outperform
2023-11-07 Iniziato Guggenheim Buy
2023-05-16 Aggiornamento Jefferies Hold → Buy
2023-03-31 Downgrade Jefferies Buy → Hold
2021-03-16 Iniziato Piper Sandler Overweight
2021-03-15 Iniziato Oppenheimer Outperform
2019-06-13 Reiterato H.C. Wainwright Buy
2019-06-13 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 Downgrade Ladenburg Thalmann Buy → Neutral
2018-08-13 Ripresa ROTH Capital Neutral
2018-01-03 Iniziato Ladenburg Thalmann Buy
2017-09-27 Ripresa ROTH Capital Buy
2017-09-22 Iniziato Jefferies Buy
2017-09-11 Iniziato JMP Securities Mkt Outperform
Mostra tutto

Savara Inc Borsa (SVRA) Ultime notizie

pulisher
Mar 13, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Mar 13, 2025
pulisher
Mar 10, 2025

Savara Inc. to Present at Leerink Global Healthcare Conference - MSN

Mar 10, 2025
pulisher
Mar 10, 2025

Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register

Mar 08, 2025
pulisher
Mar 07, 2025

Savara, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Game-Changing Finger-Prick Test Could Transform Rare Lung Disease DiagnosisWhat Makes It Special? - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

Savara Announces Participation in the Leerink Global Healthcare Conference - Joplin Globe

Mar 03, 2025
pulisher
Feb 27, 2025

Savara (SVRA) Expected to Announce Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Savara Insiders Lose Out As Stock Sinks To US$2.56 - Simply Wall St

Feb 26, 2025
pulisher
Feb 24, 2025

SVRA stock touches 52-week low at $2.58 amid market challenges - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

SVRA stock touches 52-week low at $2.58 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 23, 2025

Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86 - Defense World

Feb 23, 2025
pulisher
Feb 18, 2025

Savara Inc. Awards Stock Options and RSUs to New Employees - MSN

Feb 18, 2025
pulisher
Feb 14, 2025

SVRASavara Inc Latest Stock News & Market Updates - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

Savara Announces New Employment Inducement Grant - Milton Daily Standard

Feb 14, 2025
pulisher
Feb 14, 2025

Savara's Latest Executive Compensation Package Revealed: Key Details on New Employee Stock Awards - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

A company insider recently sold 25,000 shares of Savara Inc [SVRA]. Should You Sale? - Knox Daily

Feb 14, 2025
pulisher
Feb 10, 2025

SG Americas Securities LLC Has $158,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Feb 10, 2025
pulisher
Feb 10, 2025

SVRA’s latest rating updates from top analysts. - Knox Daily

Feb 10, 2025
pulisher
Feb 08, 2025

Positive Signs As Multiple Insiders Buy Savara Stock - Yahoo Finance UK

Feb 08, 2025
pulisher
Feb 04, 2025

Investing in Savara Inc (SVRA) Is Getting More Attractive - Knox Daily

Feb 04, 2025
pulisher
Feb 03, 2025

Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN

Feb 03, 2025
pulisher
Feb 03, 2025

Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment - MSN

Feb 03, 2025
pulisher
Jan 31, 2025

Analysts Predict How High Savara Inc (SVRA) Will Go. - Stocks Register

Jan 31, 2025
pulisher
Jan 31, 2025

JPMorgan Chase & Co. Purchases 13,420 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Molgramostim shows promise in rare lung disease treatment - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

SVRA stock touches 52-week low at $2.6 amid market challenges - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - Business Wire

Jan 30, 2025
pulisher
Jan 29, 2025

Savara Announces Participation in Upcoming Healthcare Investor Conferences - The Bakersfield Californian

Jan 29, 2025
pulisher
Jan 29, 2025

Rare Disease Pioneer Savara Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

Savara Inc (NASDAQ:SVRA) Receives $9.86 Average PT from Brokerages - Defense World

Jan 29, 2025
pulisher
Jan 26, 2025

Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 26, 2025
pulisher
Jan 26, 2025

Title: Savara Inc. Approves 2025 Executive Officers’ Target Bonus Amounts - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Savara sets executive bonus targets for 2025 - MSN

Jan 24, 2025
pulisher
Jan 23, 2025

Savara sets executive bonus targets for 2025 By Investing.com - Investing.com Australia

Jan 23, 2025
pulisher
Jan 23, 2025

Savara Sets 2025 Executive Bonus Targets - TipRanks

Jan 23, 2025
pulisher
Jan 18, 2025

Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat

Jan 17, 2025

Savara Inc Azioni (SVRA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Capitalizzazione:     |  Volume (24 ore):